Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Enfuvirtide→

Enfuvirtide Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
159519-65-0
Molecular formula
C204H301N51O64
Molecular weight
4492 g/mol
Drug class
HIV-1 fusion inhibitorgp41 HR1 domain-binding peptide
Mechanism of action
Binds the heptad-repeat 1 (HR1) region of HIV-1 gp41, preventing the conformational changes required for fusion of the viral envelope with the host-cell membrane and blocking viral entry.
Indications / reported uses
  • Treatment of HIV-1 infection in heavily treatment-experienced adults and paediatric patients aged 6 years and older in combination with other antiretroviral agents when resistance or intolerance limits other options; subcutaneous administration only

Sources: US DailyMed — FUZEON (enfuvirtide) · NLM MeSH — Enfuvirtide · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Enfuvirtide Environmental Risk Assessment (ERA) (the Enfuvirtide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.